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Abstract 
Background: Betulinic acid and betulin are triterpenes that have anticancer properties in various types of cancer. 
Unfortunately, the bioavailability and the bio‑distribution of betulinic acid and its metabolic precursor, betulin are very 
low because of poor solubility in aqueous buffers.
Methods: In this study, we examined the anticancer properties of the ester derivatives of betulin compared to 
their precursors in a malignant melanoma cell line. We assessed five amino acid esters of betulin. The compounds 
contained four basic amino acids—natural lysine (l‑Lys‑OH) and three of its derivatives (l‑Dap‑OH, l‑Dab‑OH, and 
l‑Orn‑OH)—and alanine (l‑Ala‑OH) as a negative control (amino acid without an amine group in the side chain). 
The derivatives were more soluble than their precursors (betulin and betulinic acid) in water. The betulin esters were 
tested in the malignant melanoma cell line Me‑45. To evaluate the cytotoxicity, MTT test was performed after 24, 
48 and 72 h of incubation with the test compounds at a concentration range of 0.75–100 μM. For analysis of the 
apoptotic activity, TUNEL assay was performed. Additionally, expression of caspase‑3 and PARP‑1 was investigated 
immunocytochemically.
Results: The highest biological activity was observed with the lysine ester. The results showed that the highest cyto‑
toxicity and the highest number of positively stained nuclei in metastatic melanoma Me‑45 cells were obtained after 
72 h of incubation with betulin derivatives containing lysine and ornithine.
Conclusions: The betulin ester derivatives showed enhanced antitumor activity compared to their non‑modified 
precursors. Esters of betulin can be more potent anticancer agents than their precursor as a consequence of the rapid 
bioavailability and increased concentration in cancer cells.
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Background
Cancers are a group of diseases that involve modified 
cells with dysfunctional proliferation. Melanoma is the 
most dangerous type of skin cancer observed in clini-
cal practice, and its incidence has increased over the 
past 40 years at a faster rate than any other type of can-
cer. Melanoma has a high mortality rate because of its 
prominent metastasis and its resistance to chemo- and 
radiotherapy. Currently, the standard anti-melanoma 
therapy is based on surgical procedures and chemo- and 
immunotherapy, but these methods are still ineffective. 
Many new anticancer drugs have been developed to treat 
this type of cancer. One class of drugs is the triterpe-
nes. These compounds are abundant in natural sources 
and belong to a group of isoprenoids. They have a wide 
variety of pharmacological activities [1]. We focused 
on triterpenes derived from the bark of the birch: betu-
lin and betulinic acid (the oxidation product of betulin) 
that showed anticancer properties. Previous in  vitro 
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and in  vivo studies have demonstrated that betulin and 
betulinic acid were cytotoxic and induced apoptosis in 
various tumor cells [2–4]. Another report showed that 
betulinic acid was an extremely selective compound, 
which was effective in human melanoma cells in vitro and 
in a mouse model [5]. Moreover, these substances can 
induce apoptosis in different type of cancer cells by acti-
vation of the intrinsic apoptotic pathway [6, 7]. Unfortu-
nately, both betulin and its oxidation product have very 
poor solubility in aqueous media, and consequently, their 
bio-distribution and bioavailability are limited in medi-
cal applications. However, betulin is a natural compound 
that is easily isolated from plant material and can be 
easily converted into more soluble derivatives [8]. Betu-
lin derivatives were previously shown to have increased 
solubility in water [9]. Our group synthesized five amino 
acid esters of betulin from the bark of birch (National 
patent application No PL211589). First, the cytotoxic-
ity of these derivatives was investigated using human 
epidermoid carcinoma cells (A431) and normal human 
keratinocytes (HaCaT). The promising anticancer activity 
and low toxicity towards normal human keratinocytes of 
these esters suggested that these compounds are promis-
ing candidates for further research. Additionally, because 
no successful treatment for melanoma is currently avail-
able, we studied the effects of the new derivatives of betu-
lin on a melanoma cell line.
Methods
Cells and culture conditions
A human pigmented malignant melanoma cell line was 
used (Me-45). This cell line was established in 1997 at 
the Radiobiology Department of the Center of Oncology 
in Gliwice, Poland (gift from Prof. M. Latocha) from a 
lymph node metastasis of skin melanoma from a 35-year-
old female patient. The cells were grown in DMEM 
(Sigma) with 10% fetal bovine serum (Sigma-Aldrich) and 
antibiotics (antibiotic–antimycotic Stabilized, Sigma). 
For further studies, the cells were removed by trypsiniza-
tion (Trypsin–EDTA, Sigma) and washed with PBS. The 
cells were grown in a humidified atmosphere at 37 °C and 
5% CO2.
Betulin and betulin derivatives exposition
In this study, we used betulin and betulin derivatives for 
metastatic melanoma treatment. The structures of the 
compounds are shown in Fig. 1. Synthesis of these com-
pounds was described in our previous study by Drag-
Zalesińska et al. [10]. The experimental conditions were 
based on our previous reports. For our studies, we used 
five selected betulin ester derivatives: four basic amino 
acids—natural lysine (l-Lys-OH) and three of its deriva-
tives (l-Dap-OH, l-Dab-OH, and l-Orn-OH)—and 
alanine (l-Ala-OH) as a negative control (amino acid 
without amine group in side chain) [10], as well as bet-
ulin and betulinic acid. The derivatives had increased 
solubility in water compared to their precursors, which 
was described in our earlier studies [9]. Betulin-Ala-NH2 
showed no significant inhibition of cellular proliferation. 
This result was expected because Ala is hydrophobic and 
does not have an amino group in the side chain, which 
influences the biological properties of tested derivatives. 
Based on our previous studies [10], 6 and 12.5 µM were 
selected as the concentrations of all compounds for fur-
ther investigation.
MTT assay
For determination of cell viability with betulin and its 
derivatives, MTT assay (Sigma, Germany; In  Vitro 
Toxicology assay) was used. The cells were grown on 
96-well microplates and incubated overnight to allow 
for attachment. The melanoma cells were incubated in 
all compounds for 24, 48 and 72  h at concentrations of 
0.75–100  µM. The MTT cytotoxicity assay is based on 
the colored reaction of tetrazolium salt and assesses the 
mitochondrial activity of the cells. Mitochondrial func-
tion was expressed as the percentage of the viable treated 
cells compared to the untreated control cells (without 
compounds and treated separately with DMSO). All 
experiments were independently repeated three times.
Immunocytochemical evaluation of PARP‑1 and caspase‑3
The apoptotic activity was assessed by immunocyto-
chemical determination of caspase 3 and PARP-1. Immu-
nocytochemistry analysis was performed using the ABC 
method. Cultures were harvested on 8-well microscopic 
slides (Thermo Scientific). After 24  h of exposure to 
betulin and betulin derivatives at concentrations of 6 
and 12.5  µM, cells were fixed and dehydrated using 4% 
paraformaldehyde for 10 min. Next, an ethanol gradient 
was applied. The samples were then permeabilized and 
blocked by incubation with 0.1% Triton X-100 (Sigma) 
in PBS. The proteins were visualized with a polyclonal 
mouse monoclonal antibody (1:100, anti-CASP-3 and 
PARP-1; Santa Cruz, USA Biotechnology). For conven-
tional bright-field microscopy (peroxidase-ABC labeling), 
the samples were incubated with a diaminobenzidine-
H2O2 mixture (DAKO) to visualize the peroxidase label 
and counterstained with hematoxylin (Alchem, Poland) 
for 30  s. The samples were analyzed with an upright 
light microscope (Olympus BX51, Japan). Stained cell 
numbers were evaluated by counting 100 cells in 3 ran-
domly selected fields. The analysis was carried out by two 
independent investigators. The results were judged to 
be positive if staining was observed in more than 5% of 
the cells. The intensity of immunohistochemical staining 
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was evaluated as follows: (−) negative, (no reaction), (+) 
weak, (++) moderate, and (+++) strong. All experi-
ments were repeated three times.
TUNEL assay
DNA fragmentation was evaluated using an ApopTag1 
(Qbiogene) kit. In this method, the enzyme termi-
nal deoxynucleotidyl transferase labels the 3-OH ends 
of DNA generated during apoptosis with biotinylated 
nucleotides. Immunoperoxidase staining was used to 
detect these fragments. The apoptosis detection kit ena-
bles distinction of apoptosis from necrosis by specifically 
detecting the DNA cleavage and chromatin condensation 
associated with apoptosis. Human melanoma cells were 
cultured on 8-well slides (20,000 cells per slide, Roth 
Germany) overnight for attachment. Then, the cells were 
treated with the investigated compounds at concentra-
tions of 6 and 12.5 µM for 24 h. After treatment, the cells 
were fixed with 4% formalin in PBS for 10 min and per-
meabilized with 0.2% Triton X-100 in PBS for 5  min at 
room temperature. TUNEL assay was carried out accord-
ing the manufacturer’s (Millipore) instructions. Nuclei 
were stained with hematoxylin. Then samples were 
mounted by DPX (Thermo Fisher Scientific, Germany) 
on glass slides. Cells with stained nuclei were investigated 
by counting 100 cells in 3 randomly selected fields. The 
analyses were performed by two independent investiga-
tors. Samples were evaluated with a BX51 upright light 
microscope (Olympus, Japan).
Statistical analysis
The significance of differences between the mean values 
of group of cells exposed to betulin, its derivatives and 
not treated control cells was assessed with test-T, which 
returns the probability associated with Student’s t test, 
which was carried out for each experiment individu-
ally and n ≥ 3. P ≤ 0.05 (*) was regarded as statistically 
significant.
Results and discussion
The resistance of many malignant cells to tumor treat-
ment is a major problem in cancer therapy. Novel strate-
gies are required to improve patient outcomes. Currently 
applied anticancer therapies are developed for inducing 
apoptosis or repair defects in the apoptotic pathway in 
cancer cells. Moreover, many cancer cells are resistant 
to apoptosis due to mutations in genes responsible for 
apoptotic death pathways [11]. Numerous anticancer 
strategies are based on inhibition of cell proliferation 
and promotion of cell death [12]. Natural compounds 
derived from plants are frequently used as potential anti-
cancer substances [13, 14]; these compounds are easily 
Fig. 1 Structures of betulin derivatives: a structure of amino acids used for the synthesis of betulin derivatives used for the treatment of melanoma 
cells (Me‑45); b the general structure of the 5‑element collection containing l‑amino acids
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available because of their common occurrence in nature. 
Our results obtained from proliferation assay indicated 
that the highest cytotoxicity in metastatic Me-45 mela-
noma cells was obtained after 72  h incubation with 
new betulin derivatives containing lysine and ornithine 
(IC50 = 2.456 μM; IC50 = 2.465 μM, respectively). These 
results were also observed for the Betulin-l-Dab-NH2 
compound (IC50 =  9.253  μM) compared to the precur-
sors betulin and betulinic acid (Fig. 2; Table 1). The avail-
able data indicate that triterpenes are a promising group 
of anticancer and chemopreventive agents [7, 11]. The 
most popular compounds from this group are betulin and 
betulinic acid. Numerous studies have shown that betulin 
and betulinic acid exhibit biological and pharmacologi-
cal properties, including anticancer and chemopreventive 
activities [1, 8]. Additionally, they do not affect normal 
cells [8, 15, 16]. Unfortunately their biological properties 
are limited because of the poor water solubility [2]. Betu-
lin from birch bark was modified by our research group 
with selected natural amino acids (national patent appli-
cation, No PL211589), which had increased water solu-
bility compared to that of betulin and betulinic acid. Our 
previous data confirmed that the new compounds have 
cytotoxic properties and proapoptotic activity in cancer 
cells [9].
In the current study, immunocytochemical staining of 
PARP-1 and caspase-3 in melanoma cells treated with 
betulin compounds was performed. PARP-1 is cleaved 
by caspase-3 through apoptosis, which leads to its inac-
tivation [8, 9]. The results from the immunocytochemical 
analyses of apoptotic proteins are presented in Table  2. 
Overexpression of PARP-1 was observed in melanoma 
cells after exposure to every compound: betulin and its 
derivatives achieved approximately 100%. Low expres-
sion of caspase-3 (<5% for both concentrations) was 
observed for modified and non-modified substances pre-
pared from birch bark (Table  2). Additionally, TUNEL 
assay was used to assess the number of apoptotic nuclei 
after treatment. The highest number of positively stained 
nuclei was observed in Me-45 cells after incubation with 
betulin derivatives containing ornithine, lysine, and ala-
nine and betulinic acid (Fig.  3). After incubation with 
betulin, the lowest number of apoptotic nuclei were 
noted (Table 3). In other studies, we examined the cyto-
toxicity and ability of these derivatives to induce apopto-
sis in skin cancer cells (A431) and normal keratinocytes 
(HaCaT) [10]. Our investigation suggested that selected 
derivatives of betulin can be also useful in the treatment 
of melanoma cells. The highest cytotoxicity was noted in 
Me-45 cells after incubation with new betulin derivatives 
containing lysine and ornithine. Similar results were also 
observed with the Betulin-l-Dab-NH2x2HCl compound 
compared to its precursor betulin. The highest number 
of positively stained nuclei was obtained in Me-45 cells 
after incubation with betulin derivatives containing orni-
thine, lysine and alanine as well as betulinic acid. After 
incubation with betulin, the lowest number of apoptotic 
nuclei were noted. In previous investigations, novel lysine 
esters of betulin were shown to promote apoptosis in 
tumor-sensitive and resistant pancreatic and stomach 
cell lines more effectively than betulin and betulinic acid 
[2, 9]. Orchel et  al. examined the effects of betulin and 
its acetylenic derivative 28-O-propynoylbetulin on prolif-
eration and apoptosis in human melanoma cells (G-361). 
They modified betulin through insertion of a propynol 
motif into the betulin structure at the C-28 position. 
The authors compared the cytotoxic and proapoptotic 
properties of betulin and its derivatives. The investiga-
tions demonstrated similar cytotoxicity, inhibition of the 
cell cycle and apoptosis activation in melanoma cells [7]. 
Additionally, Boryczka et al. showed that modified betu-
lin at the C-28 position had stronger cytotoxic properties 
against human and murine leukemia cells than its pre-
cursor, an acetylenic derivative and cisplatin. However, 
28-O-propynoylbetulin had less apoptotic and cytotoxic 
activity in breast and colorectal cancer cells [17]. Further-
more, Hata et  al. [18] noted that the lupine triterpenes 
showed significantly increased cytotoxicity than betulin 
in melanoma, leukemia and neuroblastoma cells.
In our study, treatment of Me-45 melanoma cells with 
the earlier described derivatives resulted in significant 
increases in apoptotic nuclei and strong cytotoxicity 
in these cells compared to cells incubated with betulin 
and betulinic acid. The immunocytochemical staining 
showed similar amounts of caspase 3 and PARP-1 after 
incubation with betulin and its selected derivatives. It is 
worth noting that we used esters of betulin with different 
numbers of free amino groups (one or two), which influ-
ence their solubility in water. Additionally, the biologi-
cal properties and activity of these esters of betulin were 
positively associated with the length of the side chain of 
the l-amino acid.
In various studies, the cytotoxic and proapoptotic 
properties of betulin and betulinic acid were demon-
strated in different melanoma cells. Moreover, the mech-
anism of this apoptotic activity was described. Betulin 
and betulinic acid increased the apoptosis of melanoma 
cells via the interaction with the mitochondrial mem-
brane and the release of cytochrome c or apoptosis 
inducing factor (AIF). Importantly, betulinic acid induces 
apoptosis in cancer cells independent of their p53 status 
[16, 19–24].
Our results demonstrated that modification of betulin 
through the addition of selected amino acids can result 
in stronger cytotoxic and proapototic effects compared 
to betulin. As shown in our studies, esters of betulin can 
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be more potent anticancer agents than their precursor as 
a consequence of more rapid availability and increased 
concentration in cancer cells. The cytotoxic and proap-
optotic mechanism of these compounds may be similar 
to betulin and betulinic acid, but this hypothesis must be 
further investigated. In a future study, we will examine 
the mechanism of apoptosis after betulin ester treatment 
by evaluating the major proteins involved in this type of 
Fig. 2 The cytotoxicity studies evaluated Me45 cells treated with betulin and its new derivatives after a 24 h; b 48 h and c 72 h where: A—Betulin‐
l‐Lys‐NH2; B—Betulin‐l‐Orn‐NH2; C—Betulin‐l‐Dab‐NH2; D—Betulin‐l‐Dap‐NH2; E—Betulin‐l‐Ala‐NH2; F—betulin; G—betulinic acid. P ≤ 0.05 (*)
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death. Elucidation of the apoptotic pathway induced after 
incubation with the analyzed compounds can help in the 
development of new anticancer strategies.
Conclusions
We concluded that the betulin ester derivatives efficiently 
enhanced antitumor activity compared to their non-
modified precursors in metastatic melanoma cells. The 
results indicated that natural compounds derived from 
betulin can be more potent anticancer agents than its 
precursor as a consequence of rapid bioavailability and 
better concentration in skin cancer cells.
Table 1 The IC50 index and  water solubility of  betulin 
derivatives evaluated for human Me45 cells
Compound IC50 for Me45 cells [µM] Water solubility
24 h 48 h 72 h
Betulin‐l‐Lys‐NH2 55.339 20.275 2.456 Very good
Betulin‐l‐Orn‐NH2 70.658 27.155 2.465 Very good
Betulin‐l‐Dab‐NH2 66.453 51.405 9.253 Very good
Betulin‐l‐Dap‐NH2 107.740 61.524 75.489 Very good
Betulin‐l‐Ala‐NH2 86.573 62.089 10.125 Very good
Betulin 24.208 42.822 30.456 Weak
Betulinic acid 22.772 22.794 15.325 Middle
Table 2 Semi-quantitative evaluation of  immunocytochemical reaction with anti-PARP-1 and anti-caspase 3 antibodies 
in Me-45 cells after exposition to betulin derivatives, after 24 h
Compound Me‑45
PARP‑1 12.5 µM PARP‑1 6 µM Casp 3 12.5 µM Casp 3 6 µM
Control cells 5%, +/++ – <5%,∓ –
Betulin‐l‐Lys‐NH2 95%, ++ 50%, +/++ 0% 0%
Betulin‐l‐Orn‐NH2 100%, ++ 98%, +/++ <5%, ∓ <5%, ∓
Betulin‐l‐Dab‐NH2 100%, +++ 100%, +++ 0% 0%
Betulin‐l‐Dap‐NH2 100%, +++ 98%, +/++ <5%, ∓ <5%,∓
Betulin‐l‐Ala‐NH2 100%, ++/+++ 90%, ++ <5%, ∓ 0%
Betulin 100%, ++/+++ 95%, ++/+++ 10%,+ <5%,∓
Betulinic acid 100%, ++/+++ 100%, ++/+++ 5‑10%, +/++ <5%, ∓
Fig. 3 Apoptotic nuclei evaluation in Me45 cells after treatment with betulin and its new derivatives at a concentration of 6 µM (TUNEL assay) 72 h 
after treatment
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